Skip to main content
SpringerLink
Log in

Varenicline

A Novel Pharmacotherapy for Smoking Cessation

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Varenicline is an orally administered small molecule with partial agonist activity at the α4β2 nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the European Medicines Agency of the EU in 2006 as an aid to smoking cessation. Subsequently, varenicline has been approved in over 80 other countries.

Varenicline is almost entirely absorbed following oral administration, and absorption is unaffected by food, smoking or the time of day. Varenicline undergoes only minimal metabolism and approximately 90% of the drug is excreted in the urine unchanged. Varenicline has a mean elimination half-life after repeated administration of approximately 24 hours in smokers. The area under the plasma concentration-time curve is increased in patients with moderate or severe renal failure. No clinically relevant varenicline-drug interactions have been identified.

In two identical, randomized, double-blind, phase III clinical trials in healthy, motivated-to-quit, mainly Caucasian smokers aged 18–75 years in the US, 12 weeks of treatment with varenicline 1 mg twice daily was associated with significantly higher abstinence rates over weeks 9–12 than sustained-release bupropion 150 mg twice daily or placebo. In a separate phase III trial, an additional 12 weeks of treatment in smokers achieving abstinence in the first 12 weeks was associated with greater abstinence through to week 52 than placebo treatment. Varenicline treatment was also associated with significantly higher rates of abstinence than placebo treatment in randomized, double-blind, clinical trials in smokers in China, Japan, Korea, Singapore, Taiwan and Thailand. In a randomized, open-label, multi-national, phase III trial, varenicline treatment was associated with a significantly higher rate of abstinence than transdermal nicotine-replacement therapy. In these trials, varenicline treatment was associated with lower urge to smoke and satisfaction from smoking in relapsers than placebo or active comparators.

In the two US phase III trials, 12 weeks of treatment with varenicline 1 mg twice daily had an acceptable safety and tolerability profile. Nausea and abnormal dreams were the most common adverse events that occurred in more varenicline than placebo recipients. The incidence and prevalence of nausea were greatest in weeks 1 and 2 of treatment, and declined thereafter. The prevalence of early adverse effects can be reduced by individual dose titration. Adverse events associated with varenicline therapy have been reported in post-marketing surveillance, including neuropsychiatric events such as depressed mood, agitation, changes in behaviour, suicidal ideation and suicide. Currently, it is unclear whether the association of varenicline therapy with these adverse events is causal, coincidental or related to smoking cessation.

Given the greater efficacy of varenicline compared with other pharmacotherapies, and the high risk of morbidity and mortality associated with continued smoking, varenicline is a valuable pharmacological aid to smoking cessation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Fig. 2
Table V

Similar content being viewed by others

References

  1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006 Nov; 3(11): e442

    Article  PubMed  Google Scholar 

  2. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004 Jun 26; 328(7455): 1519

    Article  PubMed  Google Scholar 

  3. Shearer J, Shanahan M. Cost effectiveness analysis of smoking cessation interventions. Aust N Z J Public Health 2006 Oct; 30(5): 428–34

    Article  PubMed  Google Scholar 

  4. Warner KE. Cost effectiveness of smoking-cessation therapies: interpretation of the evidence and implications for coverage. Pharmacoeconomics 1997 Jun; 11(6): 538–49

    Article  PubMed  CAS  Google Scholar 

  5. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007 Jan 24; (1): CD000031

  6. Stead L, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008 Jan 23; (1): CD000146

  7. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007 Jan 24; (1): CD006103

  8. US Department of Health and Human Services. The health consequences of smoking: nicotine addiction: a report of the Surgeon General. Rockville (MD): US Department of Health and Human Services, 1988

    Google Scholar 

  9. Jarvis MJ. Why people smoke. BMJ 2004 Jan 31; 328(7434): 277–9

    Article  PubMed  Google Scholar 

  10. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000 Mar 30; 393(1–3): 295–314

    Article  PubMed  Google Scholar 

  11. Maskos U, Molles BE, Pons S, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005 Jul 7; 436(7047): 103–7

    Article  PubMed  CAS  Google Scholar 

  12. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004 Nov 5; 306(5698): 1029–32

    Article  PubMed  CAS  Google Scholar 

  13. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998 Jan 8; 391(6663): 173–7

    Article  PubMed  CAS  Google Scholar 

  14. Whiting PJ, Lindstrom JM. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci 1988 Sep; 8(9): 3395–404

    PubMed  CAS  Google Scholar 

  15. Corringer PJ, Le Novère N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000; 40: 431–58

    Article  PubMed  CAS  Google Scholar 

  16. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005 May 19; 48(10): 3474–7

    Article  PubMed  CAS  Google Scholar 

  17. Tutka P, Zatonski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 2006 Nov–Dec; 58(6): 777–98

    PubMed  CAS  Google Scholar 

  18. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006 Aug 14–28; 166(15): 1553–9

    Article  PubMed  CAS  Google Scholar 

  19. Pfizer Inc. Chantix (varenicline tartrate) US prescribing information [online]. Available from URL: http://www.chantix.com/content/Prescribing_Information.jsp [Accessed 2008 Nov 4]

  20. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007 Mar; 52(3): 985–94

    Article  PubMed  CAS  Google Scholar 

  21. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at a7 neuronal nicotinic receptors. Mol Pharmacol 2006 Sep; 70(3): 801–5

    Article  PubMed  CAS  Google Scholar 

  22. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006 Jan; 34(1): 121–30

    Article  PubMed  CAS  Google Scholar 

  23. Faessel HM, Gibbs MA, Clark DJ, et al. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 2006 Dec; 46(12): 1439–48

    Article  PubMed  CAS  Google Scholar 

  24. Burstein AH, Fullerton T, Clark DJ, et al. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol 2006 Nov; 46(11): 1234–40

    Article  PubMed  CAS  Google Scholar 

  25. Xiao Y, Lv Y, Zhang X, et al. The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. Int J Clin Pharmacol 2009 Apr; 47(4): 246–54

    CAS  Google Scholar 

  26. Pfizer Inc. Chantix (varenicline tartrate) European prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/champix/H-699-PI-en.pdf [Accessed 2008 Nov 4]

  27. Faessel HM, Smith BJ, Gibbs MA, et al. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol 2006 Sep; 46(9): 991–8

    Article  PubMed  CAS  Google Scholar 

  28. Feng B, Obach RS, Burstein AH, et al. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 2008 Apr; 83(4): 567–76

    Article  PubMed  CAS  Google Scholar 

  29. Burstein AH, Clark DJ, O’Gorman M, et al. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. J Clin Pharmacol 2007 Nov; 47(11): 1421–9

    Article  PubMed  CAS  Google Scholar 

  30. Faessel HM, Burstein AH, Troutman MD, et al. Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. Eur J Clin Pharmacol 2008 Nov; 64(11): 1101–9

    Article  PubMed  CAS  Google Scholar 

  31. Hughes JR, Benowitz N, Hatsukami D, et al. Clarification of SRNT workgroup guidelines for measures in clinical trials of smoking cessation therapies. Nicotine Tob Res 2004 Oct; 6(5): 863–4

    Article  PubMed  Google Scholar 

  32. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006 Aug 14–28; 166(15): 1561–8

    Article  PubMed  Google Scholar 

  33. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006 Aug 14–28; 166(15): 1571–7

    Article  PubMed  CAS  Google Scholar 

  34. Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008 Jul; 24(7): 1931–41

    Article  PubMed  CAS  Google Scholar 

  35. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007 Jun; 29(6): 1040–56

    Article  PubMed  CAS  Google Scholar 

  36. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296(1): 47–55

    Article  PubMed  CAS  Google Scholar 

  37. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296(1): 56–63

    Article  PubMed  CAS  Google Scholar 

  38. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296(1): 64–71

    Article  PubMed  CAS  Google Scholar 

  39. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008 Aug; 63(8): 717–24

    Article  PubMed  Google Scholar 

  40. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007 Jun; 29(6): 1027–39

    Article  PubMed  CAS  Google Scholar 

  41. Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009 Apr; 14(3): 384–92

    Article  PubMed  Google Scholar 

  42. Fiore MC. US Public Health Service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000 Oct; 45(10): 1200–62

    PubMed  CAS  Google Scholar 

  43. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008 Nov–Dec; 32(6): 664–75

    Article  PubMed  Google Scholar 

  44. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986 Mar; 43(3): 289–94

    Article  PubMed  CAS  Google Scholar 

  45. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 2001 Feb; 3(1): 7–16

    Article  PubMed  CAS  Google Scholar 

  46. Cappelleri JC, Bushmakin AG, Baker CL, et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 2007 May; 32(5): 912–23

    Article  PubMed  Google Scholar 

  47. West R, Baker CL, Cappelleri JC, et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008 Apr; 197(3): 371–7

    Article  CAS  Google Scholar 

  48. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009, Jan; 65(2): 144–9

    Article  PubMed  CAS  Google Scholar 

  49. Williams KE, Reeves KR, Billing Jr CB, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007 Apr; 23(4): 793–801

    Article  PubMed  CAS  Google Scholar 

  50. Parsons AC, Shraim M, Inglis J, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev (Online) 2009; (1): CD006219

  51. US Food and Drug Administration. Information for healthcare professionals: Varenicline (marketed as Chantix) [online]. Available from URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/vareniclineHCP.htm [Accessed 2008 Nov 4]

  52. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32(2): 119–35

    Article  PubMed  CAS  Google Scholar 

  53. Pfizer Inc. Medication guide Chantix® (varenicline) tablets [online]. Available from URL: http://www.pfizer.com/files/products/ppi_chantix.pdf [Accessed 2009 Mar 26]

  54. Tonstad S, Davies S, Flammer M, et al. Incidence of depression in randomized, double-blind, placebo-controlled varenicline clinical trials [abstract]. 10th Annual Conference of SRNT Europe; 2008 Sep 23–26; Rome. Available from URL: http://www.srnt.org/meeting/europdf/AbstractBookSRNTEurope2008.pdf [Accessed 2009 May 28]

  55. Russ C, Davies S, Flammer M, et al. Incidence of psychiatric adverse events other than depression in randomized, double-blind, placebo-controlled varenicline clinical trials. 10th Annual Conference of SRNT Europe; 2008 Sep 23–26; Rome. Available from URL: http://www.srnt.org/meeting/europdf/AbstractBookSRNTEurope2008.pdf [Accessed 2009 May 28]

  56. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008 Jan; 103(1): 146–54

    Article  PubMed  Google Scholar 

  57. McClure JB, Swan GE, Jack L, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 2009 May; 24(5): 563–9

    Article  PubMed  Google Scholar 

  58. Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series [letter]. J Clin Psychiatry 2008 Jun; 69(6): 1016

    Article  PubMed  Google Scholar 

  59. McColl SL, Burstein AH, Reeves KR, et al. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clin Pharmacol Ther 2008 Apr; 83(4): 607–14

    Article  PubMed  CAS  Google Scholar 

  60. Freedman R. Exacerbation of schizophrenia by varenicline [letter]. Am J Psychiatry 2007 Aug; 164(8): 1269

    Article  PubMed  Google Scholar 

  61. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007 Aug; 164(8): 1269–70

    Article  PubMed  Google Scholar 

  62. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline [letter]. Am J Psychiatry 2008 Jun; 165(6): 774

    Article  PubMed  Google Scholar 

  63. Pirmoradi P, Roshan S, Nadeem SS. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm 2008 Sep 1; 65(17): 1624–6

    Article  PubMed  CAS  Google Scholar 

  64. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008 Jun; 13(6): 511–4

    PubMed  Google Scholar 

  65. Moore TJ, Cohen MR, Furberg CD. Strong safety signal seen for new varenicline risks [online]. Available from URL: http://www.ismp.org/docs/vareniclineStudy.asp [Accessed 2008 Nov 4]

  66. Hauben M, Wilson G, Reich L. A preliminary quantitative analysis of the spontaneous reporting of selected adverse events with chantix in the US FDA adverse event reporting system data base [abstract]. 10th Annual Conference of SRNT Europe; 2008 Sep 23–26; Rome. Available from URL: http://www.srnt.org/meeting/europdf/AbstractBookSRNTEurope2008.pdf [Accessed 2009 May 28]

  67. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1995

    Google Scholar 

Download references

Acknowledgements

The authors thank Giles Brooke, PhD, of Envision Pharma for assistance with preparation of the manuscript and figures. These editorial services were funded by Pfizer Inc.

Carlos Jiménez-Ruiz has received consulting fees from Pfizer, Sanofi-aventis and GlaxoSmithKline in the last 5 years. Ivan Berlin has received consulting fees from Pfizer and Sanofi-aventis in the last 3 years. Thomas Hering has received consulting fees from Pfizer, Novartis and GlaxoSmithKline in the last 10 years.

Author information

Authors and Affiliations

  1. Smokers Clinic, Community of Madrid, C/Santacruz del marcenado, 9, 28015, Madrid, Spain

    Carlos Jiménez-Ruiz

  2. Department of Pharmacology, Hôpital Pitié-Salpêtrière-Faculté de Médicine, Université P.&M. Curie-INSERM U894, Paris, France

    Ivan Berlin

  3. German Association of Pulmonologists, Berlin, Germany

    Thomas Hering

Authors
  1. Carlos Jiménez-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivan Berlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Hering
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos Jiménez-Ruiz.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiménez-Ruiz, C., Berlin, I. & Hering, T. Varenicline. Drugs 69, 1319–1338 (2009). https://doi.org/10.2165/00003495-200969100-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200969100-00003

Keywords

Search

Navigation